• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

    4/11/24 8:46:29 AM ET
    $GILD
    $UNH
    $VERV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $GILD alert in real time by email

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

    Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

    Verve Therapeutics Inc (NASDAQ:VERV)

    • On April 2, Verve Therapeutics announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease. The treatment is supposed to permanently turn off a protein called PCSK9, which helps reduce blood cholesterol levels. The company’s stock fell around 44% over the past month and has a 52-week low of $7.36 .
    • RSI Value: 25.88
    • VERV Price Action: Shares of Verve Therapeutics fell 8.5% to close at $8.01 on Wednesday.

    UnitedHealth Group Inc (NYSE:UNH)

    • On April 10, TD Cowen analyst Gary Taylor maintained UnitedHealth with a Buy and lowered the price target from $607 to $546.. The company’s stock fell around 8% over the past month. It has a 52-week low of $445.68.
    • RSI Value: 27.67
    • UNH Price Action: Shares of UnitedHealth fell 2.1% to close at $450.05 on Wednesday.

    Gilead Sciences, Inc. (NASDAQ:GILD)

    • On April 8, Gilead Sciences said it will release its first quarter 2024 financial results and guidance on Thursday, April 25, 2024, after the closing bell.. The company’s stock fell around 10% over the past month and has a 52-week low of $68.06.
    • RSI Value: 27.43
    • GILD Price Action: Shares of Gilead Sciences fell 2.6% to close at $68.12 on Wednesday.

     

    Check This Out: How To Earn $500 A Month From Citigroup Stock Ahead Of Q1 Earnings Report

    •  

     

    Get the next $GILD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD
    $UNH
    $VERV

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    3/10/2026$180.00Buy
    Jefferies
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Gilead Sciences Inc.
    $GILD
    1/7/2026$145.00Buy
    UBS
    Gilead Sciences Inc.
    $GILD
    11/24/2025$140.00Buy
    Truist
    Gilead Sciences Inc.
    $GILD
    11/13/2025$140.00Sector Outperform
    Scotiabank
    UnitedHealth Group Incorporated
    $UNH
    10/29/2025$333.00Buy → Hold
    Deutsche Bank
    UnitedHealth Group Incorporated
    $UNH
    10/14/2025$406.00Buy
    Goldman
    More analyst ratings

    $GILD
    $UNH
    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UnitedHealthcare Introduces AI Companion Empowering People with Simpler Navigation, Personal Experience

    Avery responds in natural language 24/7 with personal coverage and claims details, cost estimates, scheduling help, care options, rewards opportunities and more Avery offers customer advocates real-time insights into member experience, case history Avery helps guide members to more affordable quality care, potential savings UnitedHealthcare today introduced Avery, a generative AI companion that creates a simpler, more coordinated health care experience for members while empowering customer advocates to more efficiently respond to members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326290522/en/Avery graphic Av

    3/26/26 8:00:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

    -- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead's Inflammation Portfolio -- -- Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines -- Gilead Sciences, Inc. (NASDAQ:GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323998270/en/ The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell e

    3/23/26 6:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

    3/19/26 10:00:00 AM ET
    $DAWN
    $ENGN
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $GILD
    $UNH
    $VERV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $UNH
    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Deveydt Wayne S

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    3/19/26 4:33:58 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Montgomery Rice Valerie Md

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    3/19/26 4:34:04 PM ET
    $UNH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Stankiewicz Dennis Andrew

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    3/19/26 4:33:52 PM ET
    $UNH
    Medical Specialities
    Health Care

    $GILD
    $UNH
    $VERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Gilead Sciences with a new price target

    Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00

    3/10/26 8:40:41 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham reiterated coverage on Gilead Sciences with a new price target

    Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously

    2/11/26 7:05:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $UNH
    $VERV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by UnitedHealth Group Incorporated

    SCHEDULE 13G/A - UNITEDHEALTH GROUP INC (0000731766) (Subject)

    3/27/26 1:52:07 PM ET
    $UNH
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Gilead Sciences Inc.

    SCHEDULE 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    3/26/26 6:40:06 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Gilead Sciences Inc.

    DEF 14A - GILEAD SCIENCES, INC. (0000882095) (Filer)

    3/20/26 4:00:50 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $UNH
    $VERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CFO Rex John F bought $4,999,919 worth of shares (17,175 units at $291.12), increasing direct ownership by 9% to 203,796 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:47 PM ET
    $UNH
    Medical Specialities
    Health Care

    CEO, UHG Hemsley Stephen J bought $25,019,019 worth of shares (86,700 units at $288.57), increasing direct ownership by 15% to 679,493 units (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 6:11:45 PM ET
    $UNH
    Medical Specialities
    Health Care

    Director Flynn Timothy Patrick bought $491,786 worth of shares (1,533 units at $320.80) (SEC Form 4)

    4 - UNITEDHEALTH GROUP INC (0000731766) (Issuer)

    5/16/25 12:28:22 PM ET
    $UNH
    Medical Specialities
    Health Care

    $GILD
    $UNH
    $VERV
    Leadership Updates

    Live Leadership Updates

    View All

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    $GILD
    $UNH
    $VERV
    Financials

    Live finance-specific insights

    View All

    UnitedHealth Group Board Authorizes Payment of Quarterly Dividend

    The UnitedHealth Group (NYSE:UNH) board of directors has authorized payment of a cash dividend of $2.21 per share, to be paid on March 17, 2026, to all shareholders of record of UNH common stock as of the close of business March 9, 2026. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health

    2/25/26 6:50:00 AM ET
    $UNH
    Medical Specialities
    Health Care

    Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

    – Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af

    2/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

    2/10/26 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $UNH
    $VERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

    SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/12/24 5:52:40 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

    SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/4/24 1:52:43 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care